Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 5/20 | 0.40 |
| ▸ | CDK5 | Q00535 | 5/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 4/20 | 0.40 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.40 |
| ▸ | RET | P07949 | 1/20 | 0.40 |
| ▸ | MET | P08581 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.40 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.40 |
| ▸ | PRKACA | P17612 | 1/20 | 0.40 |
| ▸ | FLT1 | P17948 | 1/20 | 0.40 |
| ▸ | LTK | P29376 | 1/20 | 0.40 |
| ▸ | GRK5 | P34947 | 1/20 | 0.40 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.40 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14603910 | 0.83 | CHEK1 (0.37) | GSK3BCDK5CHEK1CES1CDK1 | |
| SCHEMBL9336180 | 0.75 | RYR2 (0.43) | GSK3BCDK5CHEK1PRKD3AURKA | |
| SCHEMBL390083 | 0.73 | PARP10 (0.46) | CHEK1CES1HRH1HRH4PDPK1 | |
| SCHEMBL3974015 | 0.71 | TSHR (0.38) | GSK3BCDK5CHEK1PRKD3AURKA | |
| SCHEMBL21584043 | 0.69 | FABP6 (0.45) | GSK3BCDK5CHEK1PRKD3AURKA | |
| SCHEMBL9334723 | 0.69 | CES1 (0.35) | CES1PTPRC | |
| SCHEMBL19436351 | 0.69 | PNMT (0.39) | NISCH | |
| SCHEMBL2043642 | 0.69 | — | — | |
| SCHEMBL161158 | 0.68 | — | — | |
| SCHEMBL8214913 | 0.66 | NOS2 (0.51) | NISCHALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130267498-A1 | COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2013-10-10 | — | — | US | disclosed |
| US-8399458-B2 | Compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-03-19 | — | — | US | disclosed |
| US-8399458-B2 | Compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-03-19 | — | — | US | disclosed |
| US-8399458-B2 | Compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-03-19 | — | — | US | disclosed |
| US-20120028965-A1 | COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-02 | — | — | US | disclosed |
| US-20120028965-A1 | COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-02 | — | — | US | disclosed |
| US-20120028965-A1 | COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-02 | — | — | US | disclosed |
| EP-2094712-B1 | COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMA (US) | 2011-10-12 | — | — | EP | disclosed |
| EP-2094712-B1 | COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMA (US) | 2011-10-12 | — | — | EP | disclosed |
| US-7838517-B2 | Compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-11-23 | — | — | US | disclosed |
| US-7838517-B2 | Compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-11-23 | — | — | US | disclosed |
| US-7838517-B2 | Compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-11-23 | — | — | US | disclosed |
| US-20090281082-A1 | COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-11-12 | — | — | US | disclosed |
| US-20090281082-A1 | COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-11-12 | — | — | US | disclosed |
| US-20090281082-A1 | COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-11-12 | — | — | US | disclosed |
| EP-2094712-A2 | COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | Vertex Pharmceuticals Incorporated (US) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008060597-A2 | COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-05-22 | — | — | WO | disclosed |
| WO-2008060597-A2 | COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281082-A1 | COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | MAP3K20, MAP3K6, MAP3K1 | GSK3B 258/4885CDK5 53/4885CHEK1 140/4885 |
| US-20120028965-A1 | COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | MAP3K20, MAP3K6, MAP3K1 | GSK3B 258/4885CDK5 53/4885CHEK1 140/4885 |
| US-20130267498-A1 | COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | MAP3K20, MAP3K6, MAP3K1 | GSK3B 258/4885CDK5 53/4885CHEK1 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.